Every patient is unique, so is every cancer.
PTEN and ERG biomarkers offer a personalized approach to prostate cancer evaluation. PTEN deletion and ERG gene fusions are among the most common genetic aberrations in prostate cancer, present in up to 50-70% of cases. The PTEN tumor suppressor gene is involved in the regulation of DNA repair, genomic instability, stem cell self-renewal, cellular senescence, and cell migration. The TMPRSS2: ERG fusion gene, is a transcription promoter that contributes to the proliferation and invasive capacity of cancer cells. Immunohistochemistry (IHC) offers cost-effective and sensitive and specific alternative to detect PTEN deletion and ERG gene fusions in prostate cancer.